MBX Biosciences, Inc.
MBX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001776111
In the last 90 days, MBX Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 172 institutions reported holding it in 13F filings for Q2 2026, worth $3.06B in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding MBX Biosciences, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 45 | 63 | +18 |
| Shares | 30.3M | 32.9M | +2.64M (+8.7%) |
| Value | $784.1M | $606.5M | −$177.6M (−22.6%) |
New holders (33)
Institutions that held MBX Biosciences, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (15)
Institutions that held MBX Biosciences, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Monashee Investment Management LLC | 50,000 | $1.30M |
| Maven Securities LTD | 50,000 | $1.30M |
| StemPoint Capital LP | 50,000 | $1.30M |
| Soros Fund Management LLCSuperinvestorSoros Fund Management | 30,000 | $779.4K |
| Ghisallo Capital Management LLC | 30,000 | $779.4K |
| Jane Street Group, LLC | 26,570 | $690.3K |
| Point72 (DIFC) Ltd | 24,011 | $623.8K |
| HRT Financial LP | 21,637 | $562.0K |
| Squarepoint Ops LLC | 16,470 | $427.9K |
| Point72 Asset Management, L.P. | 15,600 | $405.3K |
| Shay Capital LLC | 15,000 | $389.7K |
| Davidson Kempner Capital Management LP | 13,500 | $337.6K |
| Point72 Asia (Singapore) Pte. Ltd. | 10,706 | $278.1K |
| Capula Management Ltd | 8,362 | $217.2K |
| Aster Capital Management (DIFC) Ltd | 1,810 | $47.0K |